Allogene therapeutics, inc. (ALLO)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18
Operating expenses:
Research and development

42,042

49,363

39,995

31,774

23,403

-

10,870

122,486

-

General and administrative

15,641

15,212

15,016

14,187

13,058

14,542

11,317

12,526

2,597

Total operating expenses

57,683

64,575

55,011

45,961

36,461

33,046

22,187

135,012

2,597

Loss from operations

-57,683

-64,575

-55,011

-45,961

-36,461

-33,046

-22,187

-135,012

-2,597

Other income (expense), net:
Change in fair value of convertible note payable

-

-

0

-

-

-

19,415

-

-

Interest expense

-

-

0

-

-

-

3,358

-

-

Interest and other income, net

3,261

3,658

4,309

4,559

4,825

-

1,463

110

-

Other expenses

58

-

-

-

0

-

-

-

-

Total other income (expense), net

3,203

-

-

-

4,825

-

-

-

-

Loss before income taxes

-54,480

-61,185

-50,702

-41,402

-31,636

-30,626

-43,497

-134,902

-2,597

Benefit from income taxes

0

-105

33

-159

-100

-

0

0

-

Net loss

-54,480

-61,030

-50,735

-41,243

-31,586

-30,509

-43,497

-134,902

-2,597

Other comprehensive income:
Net unrealized gain on available-for-sale investments

465

-721

-295

756

1,099

-

-148

0

-

Net comprehensive loss

-54,015

-61,751

-51,030

-40,487

-30,487

-30,055

-43,645

-134,902

-2,597

Net loss per share, basic and diluted (in dollars per share)

-0.50

-0.60

-0.50

-0.41

-0.32

47.32

-10.71

-43.82

-0.10

Weighted-average number of shares used in computing net loss per share, basic and diluted (in shares)

108,963

104,895

102,186

99,846

97,315

82,404

4,060

3,078

26,249